Many studies have suggested that inappropriate plasma usage is common. An important factor contributing to futile plasma administration in most patients is the nonlinear relationship between coagulation-factor levels and the volume of plasma transfused. In this review, a validated mathematical model and data from the literature will be used to illuminate 3 key properties of plasma transfusion. Those properties are as follows: the effect of plasma transfusion on international normalized ratio (INR) is transient; for the same volume of transfused plasma, a greater reduction in INR is observed at higher initial INRs; and the effect of plasma transfusion on INR correction (ie, the difference between initial and final INRs) diminishes as more plasma is transfused. Frequent misunderstanding of these properties may contribute to inappropriate plasma usage. Therefore, this review will assist physicians in navigating these common pitfalls. Stronger understanding of these principles may result in a reduction of inappropriate plasma transfusions, thus potentially enhancing patient safety and reducing healthcare costs.
The practice of blood transfusion is decreasing in the United States, largely as a result of successful blood usage initiatives (ie, patient blood management [PBM] ). However, this practice remains a common therapeutic modality. 1, 2 To date, PBM programs have focused primarily on the reduction of red blood cell (RBC) transfusions. 1 However, plasma transfusion has increased in recent years. Also, the findings from multiple recent studies [3] [4] [5] suggest that most of these plasma transfusions may be inappropriate and/or not indicated.
Currently, many physicians struggle with the management of preprocedural/preoperative, laboratory-defined coagulopathic manifestations (ie, the presence of a prolonged of prothrombin time [PT] , international normalized ratio [INR] , or activated partial thromboplastin time [APTT] in a stable patient who is not bleeding). 5 The clinical benefit of using INR as an indicator of coagulopathic manifestations or, more specifically, of correcting an elevated INR preprocedurally is highly debatable.
Nevertheless, transfusing plasma for this purpose is a common practice in both academic and community-based hospitals. [6] [7] [8] [9] Given that the transfusion of plasma can present significant risks, under-and overdosing should be avoided. 10, 11 Many studies reported a high rate of inappropriate plasma transfusion in Canada, the United Kingdom, and the United States. [3] [4] [5] One plausible explanation is a lack of a clear understanding of the complex properties related to the transfusion of plasma (ie, the impermanent effect of plasma transfusion on coagulation-factor levels and the nonlinear relationship between INR reduction and the volume of plasma transfused [ Figures 1 and 2 The reduction in such a case would be minimal, although the patient would be exposed to multiple units of plasma. information. This period should be followed by slowly introducing escalating policy restrictions to ensure compliance and adherence. 23 This model has been shown to be an effective means of physician education that has reduced unnecessary plasma transfusions and overall cost. 23, 24 Although not covered in detail in this review, another key concept in the management of preprocedural/preoperative coagulopathic manifestations is the importance of platelets in the hemostatic process. For instance, the bleeding risk increases significantly when both thrombocytopenia and coagulopathic manifestations are present ( Figure 3 ). the interaction between multiple factors. Thus, an assessment for bleeding-risk stratification must take into account other variables in addition to coagulation-factors levels, as reflected by the PT/INR and/or APTT test results.
Conclusions
Physicians often encounter situations when INR reversal may be urgently needed in patients who are bleeding and/or as a prophylaxis before invasive procedures. Plasma transfusion is only one of several therapeutic options and, in many situations, is not the ideal therapeutic modality for patient treatment. Understanding the key features of plasma transfusions, from the theoretical and practical perspectives, will enable healthcare professionals to more effectively stratify patients who might benefit from plasma usage, as opposed to those who might require alternative methods of coagulation-factor supplementation and/or simple monitoring. Doing so potentially enhances patient safety and reduces overall healthcare costs. LM Supplemental material can be found at online www.labmedicine.com.
